FGF23 Beyond the Kidney: A New Bone Mass Regulator in the General Population

Abstract

Clinical studies investigating the relationship between fibroblast growth factor 23 (FGF23) and bone mass are controversial, especially in the healthy renal population. Our study is one of the forefronts investigating the relationship between FGF23 and bone mass parameters in the general population, according to age, sex, menopausal, and nutritional status. Cross-sectional study enrolling 123 volunteers between 20–80 years of age without primary osteoporosis under treatment nor secondary osteoporosis, where bone mass (bone mineral density-BMD, bone mineral content-BMC; assessed by Dual X-Ray Absorptiometry-DXA), body composition (DXA evaluation), and also the serum levels of FGF23, parathormone (PTH), 25(OH)D, bone resorption marker C-terminal telopeptide of type I collagen (CTx) and leptin were determined. FGF23 was negatively and independently associated with BMD and/or BMC in all groups. FGF23 contributed to up to 10% (p <0.05) of femoral neck BMD variance in postmenopausal women, but was not an accurate discriminator of normal versus low bone mass (AUC=0.622±0.076). FGF23 did not correlate with 25(OH)D, CTx, body weight, body composition parameters or leptin. FGF23 was independently associated with PTH in premenopausal women and men only. FGF23 was negatively associated with bone mass parameters in both sexes, but was not a fine discriminator between normal bone mass and osteopenia/osteoporosis. The mechanism through which FGF23 acts upon the bone seems independent of the nutritional status, requiring further investigation.

Key words

FGF23 - bone / calcium homeostasis - osteoporosis, osteopenia

• References

• 1 Blau JE, Collins MT. The PTH-Vitamin D-FGF23 axis. Rev Endocr Metab Disord 2015; 16: 165-174
• 2 Kawai M. The FGF23/Klotho axis in the regulation of mineral and metabolic homeostasis. Horm Mol Biol Clin Investig 2016; 28: 55-67
• 3 Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling?. J Bone Min Res 2010; 25: 2091-2097
• 4 Michigami T. Extracellular phosphate as a signaling molecule. Contrib Nephrol 2013; 180: 14-24
• 5 Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 2010; 25: 603-608
• 6 Saini RK, Kaneko I, Jurutka PW. et al. 1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int 2013; 92: 339-353
• 7 Wang H, Yoshiko Y, Yamamoto R. et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23: 939-948
• 8 Andrukhova O, Streicher C, Zeitz U. et al. FGF23 and parathyroid hormone signaling interact in kidney and bone. Mol Cell Endocrinol 2016; 436: 224-239
• 9 Komaba H, Kaludjerovic J, Hu DZ. et al. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney Int 2017; 92: 599-611
• 10 Shen J, Fu S, Song Y. Relationship of fibroblast growth factor 23 (FGF-23) serum levels with low bone mass in postmenopausal women. J Cell Biochem 2017; 118: 4454-4459
• 11 Imel EA, Liu Z, McQueen AK. et al. Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone 2016; 86: 98-105
• 12 Jovanovich A, Bùzková P, Chonchol M. et al. Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: The cardiovascular health study. J Clin Endocrinol Metab 2013; 98: 3323-3331
• 13 Mirza M, Karlsson MK, Mellstrom D. et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Min Res 2011; 26: 857-864
• 14 Grethen E, Hill KM, Jones R. et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab 2012; 97: 1655-1662
• 15 Watts NB, Bilezikian JP, Camacho PM. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pr 2010; 16: 1-37
• 16 Liu S, Tang W, Fang J. et al. Novel Regulators of Fgf23 expression and mineralization in hyp bone. Mol Endocrinol 2009; 23: 1505-1518
• 17 Carrillo-López N, Panizo S, Alonso-Montes C. et al. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 2016; 90: 77-89
• 18 Isakova T, Wahl P, Vargas GS. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
• 19 Wesseling-Perry K, Pereira RC, Wang H. et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009; 94: 511-517
• 20 Manghat P, Fraser WD, Wierzbicki AS. et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010; 21: 1853-1861
• 21 Kanaan N, Claes K, Devogelaer JP. et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010; 5: 1887-1892
• 22 Desjardins L, Liabeuf S, Renard C. et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012; 23: 2017-2025
• 23 Wu Q, Xiao DM, Fan WF. et al. Effect of serum fibroblast growth factor-23, matrix gla protein and fetuin-a in predicting osteoporosis in maintenance hemodialysis patients. Ther Apher Dial 2014; 18: 427-433
• 24 Yilmaz VT, Ozdem S, Donmez L. et al. FGF-23, a-klotho gene polymorphism and their relationship with the markers of bone metabolism in chronic peritoneal dialysis patients. Eurasian J Med 2015; 47: 115-125
• 25 Park SY, Jeong KH, Moon JY. et al. The relationship between circulating Fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol 2010; 14: 239-243
• 26 Han W, Bai X, Han L. et al. The relationship between serum fibroblast growth factor 23, Klotho, and lumbar spine bone mineral density in northern Chinese postmenopausal women. Menopause 2018; 26: 546-553
• 27 Holecki M, Chudek J, Wiȩcek A. et al. The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol 2011; 2011; 707126
• 28 Marsell R, Mirza M, Mallmin H. et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int 2009; 20: 1167-1173
• 29 Lane NE, Parimi N, Corr M. et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 2013; 28: 2325-2332
• 30 Pekkinen M, Laine CM, Mäkitie R. et al. FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents. Bone 2015; 71: 124-130
• 31 Sridharan M, Cheung J, Moore AE. et al. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: Association with biomarker of bone formation. Calcif Tissue Int 2010; 87: 398-405
• 32 Samadfam R, Richard C, Nguyen-Yamamoto L. et al. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009; 150: 4835-4845